Deutsche Bank Aktiengesellschaft Issues Positive Forecast for AstraZeneca (LON:AZN) Stock Price

AstraZeneca (LON:AZN) had its price target raised by Deutsche Bank Aktiengesellschaft from £105 to £110 in a report published on Thursday, Marketbeat Ratings reports. Deutsche Bank Aktiengesellschaft currently has a sell rating on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on AZN. Berenberg Bank upped their target price on shares of AstraZeneca from £142 to £145 and gave the company a “buy” rating in a research note on Tuesday, October 21st. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Thursday. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a report on Friday. Finally, Jefferies Financial Group restated a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research report on Monday, November 10th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average price target of £138.

AstraZeneca Trading Down 0.1%

Shares of LON:AZN traded down GBX 14 during trading on Thursday, reaching £140.12. 293,383,625 shares of the stock were exchanged, compared to its average volume of 54,962,125. The firm’s 50-day moving average price is £137.20 and its 200 day moving average price is £123.34. The firm has a market cap of £217.23 billion, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12-month low of GBX 9,573.51 and a 12-month high of £144.10. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

Insider Transactions at AstraZeneca

In other news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. 0.14% of the stock is owned by company insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.